This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
18 years and older, both genders.
Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.
FFPE/FNA sample is available.
Compliant with treatment protocol.
Patients already started ICI before enrollment.
Consolidation ICI (eg. Durvalumab).
Patients already started chemotherapy before enrollment.
Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.
Gene Solutions
Lead sponsor